Administration of Palivizumab: A Medical Provider's Perspective

Clinical Pediatrics

Volumn 42, Issue 9, 2003, Pages 821-826

  Helm, Elizabeth A ^a,b   Cummings, Ginny E ^a   Keane, Virginia ^a   King Jr , James C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEALTH INSURANCE; HOME CARE; HOSPITAL CARE; HOSPITAL PERSONNEL; HUMAN; INFANT; INFECTION PREVENTION; NURSE; PATIENT COMPLIANCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

EID: 0344395057     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280304200908     Document Type: Article

References (11)

1. Hall CB, Stevens TP, Swantz RJ, Sinkin RA, McBride JT. Development of local guidelines for prevention of respiratory syncytial viral infections. Ped Infect Dis J. 1999;18:850-853.
2. Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
3. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216.
4. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs or respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther. 1999;21:753-766.
5. Joffe S, Ray GT, Escobar GJ, Black S, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-427.
6. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie. Respiratory syncytial virus and premature infants born at 32 weeks gestation or earlier. Arch Pediatr Adolesc Med. 2000;154:55-61.
7. Oh PI, Lanctot KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Ped Infect Dis. 2002;21:512-518.
8. Paul DA, Leef KH, Chidekel A, Tran K, Eppes S. Rome delivery of palivizumab: outcomes and compliance. Pediatric Academic Societies Annual Meeting. April 28-May 1, 2001. Baltimore, Maryland.
9. Chin S, Lepow M, Berning F, Horgan M. Success rate of a regional program for palivizumab administration-a comparison of two models. Pediatric Academic Societies Annual Meeting. April 28-May 1, 2001. Baltimore, Maryland.
10. Langkamp DL, Hlavin S. Factors predicting compliance with palivizumab in high-risk infants. Am J Perinatol. 2001;18:345-352.
11. Bont L, van Vught AI, Kimpen JLL. Prophylaxis against respiratory syncytial virus in premature infants. Lancet. 1999;554:1003-1004.